CD19/BCMA CAR T-cells ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
16クロウ・深瀬症候群1
61自己免疫性溶血性貧血1

16. クロウ・深瀬症候群


臨床試験数 : 13 薬物数 : 18 - (DrugBank : 8) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 81
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05263817
(ClinicalTrials.gov)
October 8, 20211/12/2021A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and VasculitisA Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and VasculitisPOEMS Syndrome;Amyloidosis;Autoimmune Hemolytic Anemia;VasculitisBiological: CD19/BCMA CAR T-cellsZhejiang UniversityYake Biotechnology Ltd.RecruitingN/AN/AAll75Early Phase 1China

61. 自己免疫性溶血性貧血


臨床試験数 : 137 薬物数 : 127 - (DrugBank : 55) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 153
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05263817
(ClinicalTrials.gov)
October 8, 20211/12/2021A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and VasculitisA Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and VasculitisPOEMS Syndrome;Amyloidosis;Autoimmune Hemolytic Anemia;VasculitisBiological: CD19/BCMA CAR T-cellsZhejiang UniversityYake Biotechnology Ltd.RecruitingN/AN/AAll75Early Phase 1China